SUMMARY

• LAZCLUZE (lazertinib) is a kinase inhibitor indicated in combination with RYBREVANT (amivantamab-vmjw) for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) Exon 19 deletions (Exon19del) or Exon 21 L858R substitution mutations, as detected by a United States Food and Drug Administration (FDA)-approved test.¹
• LAZCLUZE is not commercially available as a solution or suspension.
• Data from pharmacokinetic and pharmacodynamic studies of crushing or splitting LAZCLUZE tablets for administration are not available. Data on the administration of LAZCLUZE tablets via a feeding tube (eg, nasogastric tube [NG-tube], gastrostomy tube [G-tube], or jejunostomy tube [J-tube]) are also not available.
• The company cannot support the administration of LAZCLUZE tablets via a feeding tube (eg, NG-tube, G-tube, or J-tube).
• The company cannot support any practices, procedures, or dosage administration techniques that deviate from the approved product labeling.

PRODUCT LABELING

• LAZCLUZE (lazertinib) [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.; https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/LAZCLUZE-pi.pdf.
• RYBREVANT (amivantamab-vmjw) [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.; https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/RYBREVANT-pi.pdf.

Literature Search

A literature search of MEDLINE^®, Embase^®, BIOSIS Previews^®, and Derwent Drug File (and/or other resources, including internal/external databases) was conducted on 16 August 2024.